ProQR Therapeutics Analyst Price Targets

ProQR Therapeutics NV

PRQRNASDAQ

Trade with Public

$1.33

0.0251.91%

最終更新: Oct 19, 3:50 PM

$1.40

0.08576.54%

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

ProQR Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for ProQR Therapeutics (PRQR).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

2S.Buy

7Buy

1Hold

Consensus RatingBuy# Analysts10Avg. Consensus PT$8Upside to Avg. PT+499.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$3
Oct 1, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Cut	Buy	$12→$8
Aug 20, 2026	B of A Securities	Alec Stranahan	Initiate	Buy	$8
Jun 29, 2026	Evercore ISI Group	Gavin Clark-Gartner	PT Raise	Outperform	$5→$6
Jun 26, 2026	Jones Trading	Catherine Novack	PT Cut	Buy	$11→$10
Jun 26, 2026	Chardan Capital	Keay Nakae	PT Cut	Buy	$4→$3
Apr 9, 2026	Chardan Capital	Keay Nakae	Maintained	Buy	$4
Nov 4, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$4
Aug 8, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$4
Jun 27, 2025	Cantor Fitzgerald	Timur Ivannikov	Maintained	Overweight	$8
Jun 27, 2025	JMP Securities	Jonathan Wolleben	Maintained	Market Outperform	$8
May 13, 2025	Oppenheimer	Andreas Argyrides	PT Cut	Outperform	$15→$9
Apr 29, 2025	Evercore ISI Group	Gavin Clark-Gartner	Initiate	Outperform	$5
Mar 14, 2025	Chardan Capital	Keay Nakae	Maintained	Buy	$4
Mar 14, 2025	HC Wainwright & Co.	Andrew Fein	PT Raise	Buy	$10→$12
Feb 12, 2025	Jones Trading	Catherine Novack	Initiate	Buy	$11
Dec 12, 2024	JMP Securities	Jonathan Wolleben	Maintained	Market Outperform	$8
Dec 12, 2024	Chardan Capital	Keay Nakae	Maintained	Buy	$4
Dec 12, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$10
Nov 8, 2024	HC Wainwright & Co.	Andrew Fein	PT Raise	Buy	$5→$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

HC Wainwright & Co. analyst Ananda Ghosh maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $12 to $8.

Benzinga Newsdesk

PRO
B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ:PRQR) with a Buy rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

Evercore ISI Group analyst Gavin Clark-Gartner maintains ProQR Therapeutics (NASDAQ:PRQR) with a Outperform and raises the price target from $5 to $6.

Benzinga Newsdesk

ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday

Top analysts change outlook on top names: BMO, Chardan, Rosenblatt, Susquehanna, Evercore, Deutsche Bank, Baird, Stephens & Co.

Avi Kapoor

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and lowers the price target from $4 to $3.

Benzinga Newsdesk

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $4 price target.

Benzinga Newsdesk

ProQR Therapeutics NV

ProQR Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

PRO
B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

ニュース

パートナーシップ

ベンジンガ・グローバル

ProQR Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

PRO
B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

People Also Watch

People Also Watch

ProQR Therapeutics NV

ProQR Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

PROB of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

PROEvercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday

PROChardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

PROChardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

ニュース

パートナーシップ

ベンジンガ・グローバル

ProQR Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROHC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

PROB of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

PROEvercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

ON Semiconductor To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Friday

PROChardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

PROChardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

People Also Watch

People Also Watch

PRO
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

PRO
B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target

PRO
HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Lowers Price Target to $8

PRO
B of A Securities Initiates Coverage On ProQR Therapeutics with Buy Rating, Announces Price Target of $8

PRO
Evercore ISI Group Maintains Outperform on ProQR Therapeutics, Raises Price Target to $6

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Lowers Price Target to $3

PRO
Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $4 Price Target